Prognostic significance of anti-aminoacyl-tRNA synthetase antibodies in polymyositis/dermatomyositis-associated interstitial lung disease: A retrospective case control study

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Hozumi, Hironao ^a   Enomoto, Noriyuki ^a   Kono, Masato ^a   Fujisawa, Tomoyuki ^a   Inui, Naoki ^a   Nakamura, Yutaro ^a   Sumikawa, Hiromitsu ^b   Johkoh, Takeshi ^c   Nakashima, Ran ^d   Imura, Yoshitaka ^d   Mimori, Tsuneyo ^d   Suda, Takafumi ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c Kinki Central Hospital of Mutual Association of Public School Teachers   (Japan)

^d KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID TRANSFER RNA LIGASE; AMINO ACID TRANSFER RNA LIGASE ANTIBODY; ANTIBODY; UNCLASSIFIED DRUG; AUTOANTIBODY; BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; DERMATOMYOSITIS; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; HUMAN TISSUE; IMMUNOPRECIPITATION; INTERSTITIAL PNEUMONIA; LUNG BIOPSY; MALE; MEDICAL RECORD; POLYMYOSITIS; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL RATE; COMPLICATION; COMPUTER ASSISTED TOMOGRAPHY; IMMUNOLOGY; KAPLAN MEIER METHOD; LUNG DISEASES, INTERSTITIAL; MIDDLE AGED; MORTALITY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL;

ADULT; AGED; AMINO ACYL-TRNA SYNTHETASES; AUTOANTIBODIES; BIOMARKERS; CASE-CONTROL STUDIES; DERMATOMYOSITIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOPRECIPITATION; KAPLAN-MEIER ESTIMATE; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; POLYMYOSITIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84961290750     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0120313     Document Type: Article

References (39)

1. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975; 292: 344-347. PMID: 1090839
2. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975; 292: 403-407. PMID: 1089199
3. Sontheimer RD. Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis siné myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness? J Am Acad Dermatol. 2002; 46: 626-636. PMID: 11907524
4. Marie I, Hachulla E, Chérin P, Dominique S, Hatron PY, Hellot MF, et al. Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum. 2002; 47: 614-622. PMID: 12522835
5. Marie I, Hatron PY, Dominique S, Cherin P, Mouthon L, Menard JF. Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients. Arthritis Rheum. 2011; 63: 3439-3447. doi: 10.1002/art.30513 PMID: 21702020
6. Won Huh J, Soon Kim D, Keun Lee C, Yoo B, Bum Seo J, Kitaichi M, et al. Two distinct clinical types of interstitial lung disease associated with polymyositis-dermatomyositis. Respir Med. 2007; 101: 1761-1769. PMID: 17428649
7. Suda T, Fujisawa T, Enomoto N, Nakamura Y, Inui N, Naito T, et al. Interstitial lung diseases associated with amyopathic dermatomyositis. Eur Respir J. 2006; 28: 1005-1012. PMID: 16837503
8. Fujisawa T, Suda T, Nakamura Y, Enomoto N, Ide K, Toyoshima M, et al. Differences in clinical features and prognosis of interstitial lung diseases between polymyositis and dermatomyositis. J Rheumatol. 2005; 32: 58-64. PMID: 15630726
9. Fujisawa T, Hozumi H, Kono M, Enomoto N, Hashimoto D, Nakamura Y, et al. Prognostic factors for myositis-associated interstitial lung disease. PLoS One. 2014; 9: e98824. doi: 10.1371/journal.pone.0098824 PMID: 24905449
10. Gunawardena H, Betteridge ZE, McHugh NJ. Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression. Rheumatology (Oxford). 2009; 48: 607-612. doi: 10.1093/rheumatology/kep078 PMID: 19439503
11. Yoshifuji H, Fujii T, Kobayashi S, Imura Y, Fujita Y, Kawabata D, et al. Anti-aminoacyl-tRNA synthetase antibodies in clinical course prediction of interstitial lung disease complicated with idiopathic inflammatory myopathies. Autoimmunity. 2006; 39: 233-241. PMID: 16769657
12. Love LA, Leff RL, Fraser DD, Targoff IN, Dalakas M, Plotz PH, et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore). 1991; 70: 360-374. PMID: 1659647
13. Hoshino K, Muro Y, Sugiura K, Tomita Y, Nakashima R, Mimori T. Anti-MDA5 and anti-TIF1-gamma antibodies have clinical significance for patients with dermatomyositis. Rheumatology (Oxford). 2010; 49: 1726-1733. doi: 10.1093/rheumatology/keq153 PMID: 20501546
14. Nakashima R, Imura Y, Kobayashi S, Yukawa N, Yoshifuji H, Nojima T, et al. The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody. Rheumatology (Oxford). 2010; 49: 433-440. doi: 10.1093/rheumatology/kep375 PMID: 20015976
15. Gono T, Kawaguchi Y, Satoh T, Kuwana M, Katsumata Y, Takagi K, et al. Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis. Rheumatology (Oxford). 2010; 49: 1713-1719. doi: 10.1093/rheumatology/keq149 PMID: 20498012
16. Hervier B, Benveniste O. Clinical heterogeneity and outcomes of antisynthetase syndrome. Curr Rheumatol Rep. 2013; 15: 349. doi: 10.1007/s11926-013-0349-8 PMID: 23794106
17. Hamaguchi Y, Fujimoto M, Matsushita T, Kaji K, Komura K, Hasegawa M, et al. Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies: heterogeneity within the syndrome. PLoS One. 2013; 8: e60442. doi: 10.1371/journal.pone.0060442 PMID: 23573256
18. Aggarwal R, Cassidy E, Fertig N, Koontz DC, Lucas M, Ascherman DP, et al. Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients. Ann Rheum Dis. 2014; 73: 227-232. doi: 10.1136/annrheumdis-2012-201800 PMID: 23422076
19. Richards TJ, Eggebeen A, Gibson K, Yousem S, Fuhrman C, Gochuico BR, et al. Characterization and peripheral blood biomarker assessment of anti-Jo-1 antibody-positive interstitial lung disease. Arthritis Rheum. 2009; 60: 2183-2192. doi: 10.1002/art.24631 PMID: 19565490
20. Yousem SA, Schneider F, Bi D, Oddis CV, Gibson K, Aggarwal R. The pulmonary histopathologic manifestations of the anti-PL7/antithreonyl transfer RNA synthetase syndrome. Hum Pathol. 2014; 45: 1199-1204. doi: 10.1016/j.humpath.2014.01.018 PMID: 24767252
21. Schneider F, Yousem SA, Bi D, Gibson KF, Oddis CV, Aggarwal R. Pulmonary pathologic manifestations of anti-glycyl-tRNA synthetase (anti-EJ)-related inflammatory myopathy. J Clin Pathol. 2014; 67: 678-683. doi: 10.1136/jclinpath-2014-202367 PMID: 24891607
22. Sato S, Hoshino K, Satoh T, Fujita T, Kawakami Y, Fujita T, et al. RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: Association with rapidly progressive interstitial lung disease. Arthritis Rheum. 2009; 60: 2193-2200. doi: 10.1002/art.24621 PMID: 19565506
23. Nakashima R, Imura Y, Hosono Y, Seto M, Murakami A, Watanabe K, et al. The multicenter study of a new assay for simultaneous detection of multiple anti-aminoacyl-tRNA synthetases in myositis and interstitial pneumonia. PLoS One. 2014; 9: e85062. doi: 10.1371/journal.pone.0085062 PMID: 24454792
24. Tanizawa K, Handa T, Nakashima R, Kubo T, Hosono Y, Watanabe K, et al. HRCT features of interstitial lung disease in dermatomyositis with anti-CADM-140 antibody. Respir Med. 2011; 105: 1380-1387. doi: 10.1016/j.rmed.2011.05.006 PMID: 21632230
25. American Thoracic Society; European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med. 2002; 165: 277-304. PMID: 11790668
26. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011; 183: 788-824. doi: 10.1164/rccm.2009-040GL PMID: 21471066
27. ST PMID: 24032382
28. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med. 2000; 161: 646-664. PMID: 10673212
29. Hansell DM, Bankier AA, MacMahon H, McLoud TC, Müller NL, Remy J. Fleischner Society: glossary of terms for thoracic imaging. Radiology. 2008; 246: 697-722. doi: 10.1148/radiol.2462070712 PMID: 18195376
30. Fischer A, West SG, Swigris JJ, Brown KK, du Bois RM. Connective tissue disease-associated interstitial lung disease: a call for clarification. Chest. 2010; 138: 251-256. doi: 10.1378/chest.10-0194 PMID: 20682528
31. Suda T, Kono M, Nakamura Y, Enomoto N, Kaida Y, Fujisawa T, et al. Distinct prognosis of idiopathic nonspecific interstitial pneumonia (NSIP) fulfilling criteria for undifferentiated connective tissue disease (UCTD). Respir Med. 2010; 104: 1527-1534. doi: 10.1016/j.rmed.2010.04.022 PMID: 20483576
32. Marie I, Josse S, Hatron PY, Dominique S, Hachulla E, Janvresse A, et al. Interstitial lung disease in anti-Jo-1 patients with antisynthetase syndrome. Arthritis Care Res (Hoboken). 2013; 65: 800-808. doi: 10.1002/acr.21895 PMID: 23203765
33. Cottin V, Thivolet-Béjui F, Reynaud-Gaubert M, Cadranel J, Delaval P, Ternamian PJ, et al. Interstitial lung disease in amyopathic dermatomyositis, dermatomyositis and polymyositis. Eur Respir J. 2003; 22: 245-250. PMID: 12952255
34. Tanizawa K, Handa T, Nakashima R, Kubo T, Hosono Y, Aihara K, et al. The prognostic value of HRCT in myositis-associated interstitial lung disease. Respir Med. 2013; 107: 745-752. doi: 10.1016/j.rmed.2013.01.014 PMID: 23485097
35. Kalluri M, Sahn SA, Oddis CV, Gharib SL, Christopher-Stine L, Danoff SK, et al. Clinical profile of anti-PL-12 autoantibody. Cohort study and review of the literature. Chest. 2009; 135: 1550-1556. doi: 10.1378/chest.08-2233 PMID: 19225060
36. Takato H, Waseda Y, Watanabe S, Inuzuka K, Katayama N, Ichikawa Y, et al. Pulmonary manifestations of anti-ARS antibody positive interstitial pneumonia - with or without PM/DM. Respir Med. 2013; 107: 128-133. doi: 10.1016/j.rmed.2012.09.005 PMID: 23137883
37. Douglas WW, Tazelaar HD, Hartman TE, Hartman RP, Decker PA, Schroeder DR, et al. Polymyositis-dermatomyositis-associated interstitial lung disease. Am J Respir Crit Care Med. 2001; 164: 1182-1185. PMID: 11673206
38. Tazelaar HD, Viggiano RW, Pickersgill J, Colby TV. Interstitial lung disease in polymyositis and dermatomyositis. Clinical features and prognosis as correlated with histologic findings. Am Rev Respir Dis. 1990; 141: 727-733. PMID: 2310101
39. Watanabe K, Handa T, Tanizawa K, Hosono Y, Taguchi Y, Noma S, et al. Detection of antisynthetase syndrome in patients with idiopathic interstitial pneumonias. Respir Med. 2011; 105: 1238-1247. doi: 10.1016/j.rmed.2011.03.022 PMID: 21514811